Payment overview · 2025
General Payments
$3,802.84
174 reported records · 25 companies
Healthcare provider profile · identity verified
Baoen Jiang, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1528140597
Verified facts
What the public records show
CMS Open Payments records show Baoen Jiang, M.D. received $3,802.84 in general payments during 2025 across 174 reported records.
GlaxoSmithKline, LLC. accounted for 12.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nexletol, Qulipta, Rayaldee, Rybelsus, Shingrix, Trelegy Ellipta, Vemlidy, Verquvo, Voquezna, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 420 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 428 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 564 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 832 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 369 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 832 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rayaldee by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Voquezna by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $491.58 | 12.9% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $464.61 | 12.2% | 21 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $413.43 | 10.9% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $329.22 | 8.7% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $318.17 | 8.4% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $238.44 | 6.3% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $235.89 | 6.2% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $222.27 | 5.8% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $194.09 | 5.1% | 9 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $140.25 | 3.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.22 | 3.6% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $100.68 | 2.6% | 5 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $80.55 | 2.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.48 | 1.8% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $66.35 | 1.7% | 4 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $49.35 | 1.3% | 2 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $48.94 | 1.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.16 | 1.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $33.83 | 0.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $25.06 | 0.7% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.00 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.86 | 0.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.42 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,722.29 | 170 |
| Education | $80.55 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $345.81 | 17 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $329.22 | 18 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $283.91 | 13 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $235.89 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $222.27 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $208.87 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $206.78 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $194.38 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $179.22 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.45 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.68 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $140.25 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $135.22 | 7 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $116.57 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $114.30 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $100.68 | 5 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $80.55 | 4 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $76.75 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $69.02 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $66.35 | 4 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $49.35 | 2 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.16 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 420 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 564 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 832 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 428 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 144 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 230 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 267 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 369 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
420 | 95 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
428 | 85 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
151 | 26 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
94 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
564 | 127 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
125 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
832 | 163 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
369 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
126 | 126 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
230 | 149 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
267 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
832 | 163 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
204 | 34 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
144 | 38 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 3740 | 642 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2142 | 492 |
| Amlodipine Besylate | Amlodipine Besylate | 2040 | 483 |
| Losartan Potassium | Losartan Potassium | 1613 | 390 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1521 | 330 |
| Omeprazole | Omeprazole | 1395 | 308 |
| Metformin Hcl | Metformin Hcl | 1374 | 296 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1234 | 321 |
| Metoprolol Succinate | Metoprolol Succinate | 1229 | 307 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1226 | 255 |
| Donepezil Hcl | Donepezil Hcl | 1069 | 192 |
| Fluticasone Propionate | Fluticasone Propionate | 883 | 251 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 881 | 190 |
| Alendronate Sodium | Alendronate Sodium | 877 | 165 |
| Raloxifene Hcl | Raloxifene Hcl | 860 | 152 |
| Ammonium Lactate | Ammonium Lactate | 844 | 242 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 840 | 161 |
| Jardiance | Empagliflozin | 832 | 163 |
| Dexlansoprazole Dr | Dexlansoprazole | 740 | 142 |
| Mirtazapine | Mirtazapine | 699 | 146 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 672 | 201 |
| Mometasone Furoate | Mometasone Furoate | 638 | 179 |
| Clobetasol Propionate | Clobetasol Propionate | 634 | 211 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 617 | 136 |
| Halobetasol Propionate | Halobetasol Propionate | 602 | 231 |
| Meclizine Hcl | Meclizine Hcl | 581 | 231 |
| Bepotastine Besilate | Bepotastine Besilate | 572 | 136 |
| Farxiga | Dapagliflozin Propanediol | 564 | 127 |
| Celecoxib | Celecoxib | 556 | 199 |
| Diclofenac Sodium | Diclofenac Sodium | 529 | 215 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 521 | 212 |
| Restasis | Cyclosporine | 474 | 94 |
| Simvastatin | Simvastatin | 457 | 114 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 433 | 158 |
| Linzess | Linaclotide | 428 | 85 |
| Creon | Lipase/Protease/Amylase | 420 | 95 |
| Azelastine Hcl | Azelastine Hcl | 412 | 124 |
| Montelukast Sodium | Montelukast Sodium | 395 | 70 |
| Finasteride | Finasteride | 390 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 374 | 104 |
| Vemlidy | Tenofovir Alafenamide | 369 | 43 |
| Icosapent Ethyl | Icosapent Ethyl | 337 | 140 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 336 | 135 |
| Ketoconazole | Ketoconazole | 334 | 77 |
| Telmisartan | Telmisartan | 333 | 96 |
| Azithromycin | Azithromycin | 328 | 256 |
| Trazodone Hcl | Trazodone Hcl | 328 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 298 | 63 |
| Gabapentin | Gabapentin | 293 | 71 |
| Allopurinol | Allopurinol | 286 | 54 |
| Eliquis | Apixaban | 282 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 270 | 115 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 267 | 66 |
| Clonazepam | Clonazepam | 265 | 66 |
| Tradjenta | Linagliptin | 260 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 255 | 62 |
| Famotidine | Famotidine | 253 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 245 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 45 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 230 | 149 |
| Myrbetriq | Mirabegron | 225 | 35 |
| Januvia | Sitagliptin Phosphate | 213 | 41 |
| Trulicity | Dulaglutide | 204 | 34 |
| Glimepiride | Glimepiride | 196 | 41 |
| Hydrocortisone | Hydrocortisone | 195 | 79 |
| Atenolol | Atenolol | 191 | 48 |
| Carvedilol | Carvedilol | 188 | 39 |
| Xarelto | Rivaroxaban | 188 | 34 |
| Loperamide | Loperamide Hcl | 183 | 127 |
| Glipizide Er | Glipizide | 181 | 39 |
| Folic Acid | Folic Acid | 179 | 55 |
| Colchicine | Colchicine | 178 | 42 |
| Lisinopril | Lisinopril | 175 | 44 |
| Metformin Hcl Er | Metformin Hcl | 168 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 167 | 134 |
| Procto-Med Hc | Hydrocortisone | 167 | 54 |
| Synthroid | Levothyroxine Sodium | 151 | 26 |
| Furosemide | Furosemide | 149 | 41 |
| Mupirocin | Mupirocin | 149 | 78 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 147 | 31 |
| Rybelsus | Semaglutide | 144 | 38 |
| Amoxicillin | Amoxicillin | 138 | 95 |
| Ibuprofen | Ibuprofen | 138 | 102 |
| Memantine Hcl Er | Memantine Hcl | 138 | 21 |
| Nitroglycerin | Nitroglycerin | 138 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 29 |
| Alcohol Pads | Alcohol Antiseptic Pads | 130 | 68 |
| Meloxicam | Meloxicam | 129 | 47 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 126 | 126 |
| Nexium | Esomeprazole Magnesium | 125 | 29 |
| Cyclosporine | Cyclosporine | 124 | 54 |
| Lidocaine | Lidocaine | 121 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 120 | 28 |
| Ciclopirox | Ciclopirox | 113 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 27 |
| Sertraline Hcl | Sertraline Hcl | 105 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 60 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 103 | 26 |
| Ezetimibe | Ezetimibe | 101 | 25 |
| Ranolazine Er | Ranolazine | 100 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 18 |
| Prolia | Denosumab | 94 | 64 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 84 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 83 | 39 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 83 | 33 |
| Ciclopirox | Ciclopirox Olamine | 81 | 43 |
| Pregabalin | Pregabalin | 81 | 19 |
| Proctozone-Hc | Hydrocortisone | 80 | 30 |
| Dutasteride | Dutasteride | 78 | 13 |
| Edarbi | Azilsartan Medoxomil | 78 | 13 |
| Clotrimazole | Clotrimazole | 77 | 20 |
| Enalapril Maleate | Enalapril Maleate | 77 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 75 | 12 |
| Nifedipine Er | Nifedipine | 75 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 14 |
| Potassium Chloride | Potassium Chloride | 74 | 19 |
| Naproxen | Naproxen | 73 | 36 |
| Livalo | Pitavastatin Calcium | 72 | 18 |
| Lansoprazole | Lansoprazole | 71 | 11 |
| Memantine Hcl | Memantine Hcl | 70 | 14 |
| Alprazolam | Alprazolam | 69 | 17 |
| Lactulose | Lactulose | 69 | 31 |
| Fluocinonide | Fluocinonide | 65 | 25 |
| Acarbose | Acarbose | 62 | 14 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 62 | 31 |
| Methimazole | Methimazole | 61 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 61 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 15 |
| Lubiprostone | Lubiprostone | 59 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 57 | 15 |
| Spironolactone | Spironolactone | 56 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 45 |
| Sucralfate | Sucralfate | 52 | 13 |
| Ursodiol | Ursodiol | 52 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 51 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 13 |
| Mupirocin | Mupirocin Calcium | 47 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 46 | 21 |
| Fenofibrate | Fenofibrate,micronized | 44 | suppressed |
| Kerendia | Finerenone | 44 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 44 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 31 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 42 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 41 | 33 |
| Valacyclovir | Valacyclovir Hcl | 41 | 28 |
| Baclofen | Baclofen | 40 | 16 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Mesalamine | Mesalamine | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 27 |
| Single Use Swab | Alcohol Antiseptic Pads | 38 | 17 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 37 | suppressed |
| Prednisone | Prednisone | 37 | 19 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 37 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 17 |
| Denta 5000 Plus | Fluoride (Sodium) | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Incruse Ellipta | Umeclidinium Bromide | 34 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 32 | 17 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Qulipta | Atogepant | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Febuxostat | Febuxostat | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Repaglinide | Repaglinide | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Dexilant | Dexlansoprazole | 29 | 17 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Rayaldee | Calcifediol | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 25 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 25 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 24 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Tacrolimus | Tacrolimus | 24 | 13 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 17 |
| Gemtesa | Vibegron | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 23 | suppressed |
| Easy Comfort Alcohol Pad | Alcohol Antiseptic Pads | 22 | 13 |
| Verquvo | Vericiguat | 22 | suppressed |
| Voquezna | Vonoprazan Fumarate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 19 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Entecavir | Entecavir | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 13 |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 16 |
| Ramelteon | Ramelteon | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Clindamycin Phos-Benzoyl Perox | Clindamycin Phos/Benzoyl Perox | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | 11 |
| Terconazole | Terconazole | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Ibsrela | Tenapanor Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,802.84 · 174 records | GlaxoSmithKline, LLC. | AIRSUPRA, Auvelity, BREZTRI, Brinsupri, CAPVAXIVE, CREON, Cologuard Collection Kit, DUPIXENT, EVENITY, FARXIGA, Fluad, Flucelvax, GEMTESA, GLYCATE, JARDIANCE, LINZESS, LODOCO, Leqembi, MOUNJARO, NEXLETOL, NUCALA, OTEZLA, Ozempic, QULIPTA, RAYALDEE, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, Vemlidy, YUPELRI, ZENPEP, ZEPBOUND, ZORYVE | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error